Key result
Polynesian ethnicity is linked to younger presentation and ~32% lower CK normalization in anti-HMGCR myopathy.
Why the study?
Polynesians have a higher incidence of anti-HMGCR myopathy in New Zealand, but ethnic differences in phenotype and outcome are not known.
Are there ethnic differences in disease phenotype and outcomes between Polynesian and New Zealand European patients with anti-HMGCR myopathy?
Cohort (n=83)
Are there ethnic differences in disease phenotype and outcomes between Polynesian and New Zealand European patients with anti-HMGCR myopathy?
Polynesian patients with anti-HMGCR myopathy present at a younger age and have lower rates of creatine kinase normalization compared to New Zealand Europeans, highlighting a disproportionate disease burden.
Answers are grounded in this paper and cite their sources.
Polynesian ethnicity may warrant earlier anti-HMGCR myopathy screening; leaves open mechanistic and outcome disparities for prospective study.
OBJECTIVES: Anti-3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR) myopathy is an immune-mediated necrotizing myopathy strongly associated with statin use in adults. Polynesians have a higher incidence of anti-HMGCR myopathy in New Zealand (NZ), but ethnic differences in phenotype and outcome are not known. METHODS: Ninety-one patients with anti-HMGCR myopathy were identified based on anti-HMGCR positivity by immunoprecipitation assay. Prioritized ethnicity data were used to identify 35 Polynesian and 48 NZ European patients to include in the cohort. Clinical records were accessed and information on disease phenotype, treatment and outcome was obtained. RESULTS: Polynesian patients were younger than NZ European patients at presentation (median 64 vs 71 years P = 0.009). They were less likely to normalize their creatine kinase (CK) over the follow-up period (54.2% vs 79.2%, P = 0.016), even after controlling for length of follow-up. There were no other significant differences in disease phenotype or outcome found. CONCLUSION: In addition to having higher incidence of anti-HMGCR myopathy, Polynesians are affected at a younger age and are less likely to achieve normal CK levels despite treatment over similar follow-up periods. The disproportionate burden of disease in this group should prompt early assessment of a Polynesian patient who presents with muscle symptoms while on a statin.
No takes yet. Share an insight, caveat, or question.
Anderson et al. (2025) conducted a cohort in Anti-HMGCR myopathy (n=83). Polynesian ethnicity vs. NZ European ethnicity was evaluated on Normalization of creatine kinase (CK) over the follow-up period (p=0.016). Polynesian patients with anti-HMGCR myopathy presented younger and were less likely to normalize creatine kinase than NZ Europeans.
Synapse has enriched 10 related papers. Consider them for comparative context: